TAGLIAZUCCHI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.766
NA - Nord America 3.300
EU - Europa 2.854
SA - Sud America 429
AF - Africa 86
OC - Oceania 12
Totale 10.447
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.199
CN - Cina 1.202
IT - Italia 1.139
SG - Singapore 1.110
DE - Germania 419
VN - Vietnam 374
HK - Hong Kong 346
BR - Brasile 319
SE - Svezia 272
GB - Regno Unito 224
KR - Corea 205
RU - Federazione Russa 152
FR - Francia 129
FI - Finlandia 111
ID - Indonesia 93
IN - India 80
BD - Bangladesh 69
ES - Italia 61
NL - Olanda 59
CA - Canada 58
JP - Giappone 47
IQ - Iraq 43
LT - Lituania 38
AR - Argentina 34
IE - Irlanda 34
PL - Polonia 33
CH - Svizzera 30
BE - Belgio 27
MX - Messico 25
ZA - Sudafrica 25
PK - Pakistan 22
AT - Austria 19
TR - Turchia 19
UA - Ucraina 19
CL - Cile 17
MY - Malesia 17
UZ - Uzbekistan 17
EC - Ecuador 16
IR - Iran 15
SA - Arabia Saudita 15
MA - Marocco 13
CZ - Repubblica Ceca 12
PH - Filippine 12
PY - Paraguay 12
TW - Taiwan 12
KE - Kenya 11
TN - Tunisia 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
BG - Bulgaria 10
CO - Colombia 10
GR - Grecia 9
AU - Australia 8
ET - Etiopia 7
NP - Nepal 7
LI - Liechtenstein 6
NO - Norvegia 6
RO - Romania 6
RS - Serbia 6
BY - Bielorussia 5
DZ - Algeria 5
JM - Giamaica 5
JO - Giordania 5
KZ - Kazakistan 5
MO - Macao, regione amministrativa speciale della Cina 5
TH - Thailandia 5
UY - Uruguay 5
AL - Albania 4
AZ - Azerbaigian 4
CR - Costa Rica 4
DK - Danimarca 4
EG - Egitto 4
IL - Israele 4
LV - Lettonia 4
NZ - Nuova Zelanda 4
PE - Perù 4
PT - Portogallo 4
BH - Bahrain 3
GE - Georgia 3
HU - Ungheria 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
SN - Senegal 3
DO - Repubblica Dominicana 2
EE - Estonia 2
GH - Ghana 2
KG - Kirghizistan 2
LU - Lussemburgo 2
NG - Nigeria 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SV - El Salvador 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CY - Cipro 1
GA - Gabon 1
GT - Guatemala 1
Totale 10.438
Salva come PNG Salva come JPEG
Città #
Singapore 687
Santa Clara 633
Hefei 584
Ashburn 380
San Jose 373
Hong Kong 333
Seoul 187
Modena 181
Council Bluffs 167
Frankfurt am Main 163
Ho Chi Minh City 138
Chandler 134
London 131
New York 111
Nyköping 111
Beijing 106
Los Angeles 99
Bologna 98
Jakarta 77
Hanoi 76
Helsinki 74
The Dalles 68
Milan 63
Reggio Emilia 58
Munich 57
Parma 57
Boardman 55
Moscow 46
Shanghai 42
Lauterbourg 41
Chicago 37
Fairfield 36
Orem 36
Dallas 35
São Paulo 34
Buffalo 32
Kent 31
Dublin 28
Warsaw 27
Houston 25
Amsterdam 24
Seattle 24
Lappeenranta 23
Rome 23
Formigine 22
Madrid 21
Padova 18
Princeton 18
Tokyo 18
Da Nang 17
San Diego 17
Stockholm 17
Turin 17
Chennai 16
Nuremberg 16
Piacenza 16
Denver 15
Leuven 15
Phoenix 15
Wilmington 15
Zurich 15
Decatur 14
Salt Lake City 14
Tashkent 14
Toronto 14
Atlanta 13
Barcelona 13
Boston 13
Manchester 13
Paris 13
Sassuolo 13
Cambridge 12
Düsseldorf 12
Hangzhou 12
Johannesburg 12
Osnabrück 12
Washington 12
Baghdad 11
Ferrara 11
Guangzhou 11
Ottawa 11
Perugia 11
Poplar 11
Rio de Janeiro 11
Santiago 11
Vienna 11
Brooklyn 10
Haiphong 10
Hamburg 10
Mexico City 10
Nairobi 10
Portsmouth 10
Tehran 10
Turku 10
Woodbridge 10
Biên Hòa 9
Brussels 9
Charlotte 9
Naples 9
Redondo Beach 9
Totale 6.473
Salva come PNG Salva come JPEG
Nome #
Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting 311
Designing selective Cys-ligands to unpair the binding of the Human Transcription Enhancer Associated Domain 4 (hTEAD-4) with its modulators to halt cancer cell growth 298
Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth 286
Exploiting Forster Resonance Energy Transfer (FRET) in the characterization of YAP:TEAD complex disruption 266
Development of a novel class of YAP:TEAD interface-3 molecular disruptors to treat colorectal carcinoma 240
A toolbox of biophysical and analytical assays helps to confirm the activity of novel hTS dimer disrupters (Ddis) with anticancer properties 238
design, synthesis and biological evaluation of novel YAP:TEAD complex disruptors for thetreatment of colorectal cancer 237
Serum Mass Spectrometry Proteomics and Protein Set Identification in Response to FOLFOX-4 in Drug-Resistant Ovarian Carcinoma 228
Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase 228
Repurposing the trypanosomatidic gsk kinetobox for the inhibition of parasitic pteridine and dihydrofolate reductases 225
A dual-Omics approach to identify the modulated proteins/genes in THP-1 cells infected with different drug resistant L. infantum clinical isolates. 224
Applying optical tweezers technology to reveal Thymidylate Synthase interactions with its consensus mRNA 219
LC-MS serum proteomics reveals a panel of proteins prognostic of positive responsiveness to bevacizumab therapy in late-stages ovarian cancer patients 219
Identification of a Quinone Derivative as a YAP/TEAD Activity Modulator from a Repurposing Library 210
Current Treatments to Control African Trypanosomiasis and One Health Perspective 208
Advances in the set-up of a fluorescence- anisotropy assay for the search of novel inhibitors of the tead-4 complexes 207
Lead optimization of human thymidylate synthase dimer disrupters: from computational studies to evaluation of their biological profiles 205
Coupling a microwave-assisted process with HPLC-ELSD for the extraction, purification and analysis of bioactive policosanols from beeswax 203
Enhanced anticancer effect of thymidylate synthase dimer disrupters by promoting intracellular accumulation 202
Targeting the dimer-monomer equilibrium of thymidylate synthase, to accelerate protein degradation and cancer cell growth inhibition 201
Lead-optimization process and characterization of the dissociative effect applied to new dimer disrupters of human Thymidylate Synthase 197
Structural bases for the synergistic inhibition of human thymidylate synthase and ovarian cancer cell growth by drug combinations 193
Exploring thymidylate synthase mRNA binding site 1 and human TS protein interaction with optical tweezers and bicistronic expression assay 190
The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents 189
Precision medicine through proteomics studies in drug resistant colorectal cancer 187
Characterization and Valorization of the Agricultural Waste Obtained from Lavandula Steam Distillation for Its Reuse in the Food and Pharmaceutical Fields 186
UHPLC-MS/MS screening of the hTEAD surface for the identification of novel allosteric inhibitors with anticancer activity 184
Exploiting the Optical Tweezer technology to reveal thymidylate synthase interactions with its consensus mRNA 183
Expression, purification, and characterization of Transcriptional Enhancer Associated Domain (hTEAD4), a promising target for anticancer agents 180
Development of a sensitive biochemical tool to assess the expression levels of recombinant ectopic proteins in in vitro engineered cellular systems 180
Advancing sustainable drug development: comparative preclinical study of H80 and Miltefosine using imaging and proteomics 179
EXPLOITING THE OPTICAL TWEEZER, A SINGLE MOLECULE TECHNOLOGY, TO REVEAL THYMIDYLATE SYNTHASE INTERACTIONS WITH ITS CONSENSUS mRNA 178
Identification of Innovative Folate Inhibitors Leveraging the Amino Dihydrotriazine Motif from Cycloguanil for Their Potential as Anti-Trypanosoma brucei Agents 178
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective 175
Cellular uptake and metabolic degradation of a conjugate of folic acid with an anticancer peptide targeting the human Thymidylate synthase enzyme 175
Label-Free Mass Spectrometry Proteomics Reveals Different Pathways Modulated in THP-1 Cells Infected with Therapeutic Failure and Drug Resistance Leishmania infantum Clinical Isolates 173
Insights into host-target interaction from the proteome modulation analysis through untargeted LC-MS/MS Proteomics of drug resistant L infantum-THP1 infected cells 171
Biochemical characterization of the feedforward loop between CDK1 and FOXM1 in epidermal stem cells 171
Leveraging proteomic, bioinformatic and ecotoxicology models to select new targets overcoming L. Infantum drug resistent 167
LC-MS/MS proteomics for the rapid and selective screening of drug resistances in Leishmania infantum clinical isolates 166
Deciphering Host–Parasite Interplay in Leishmania Infection through a One Health View of Proteomics Studies on Drug Resistance 164
Investigating the mechanism of action of the antiparasitic agent H80 through imaging techniques 163
Optimization of chemical-biological tools for characterizing the activity of dissociative inhibitor of human thymidylate synthase 154
Drug discovery of pyrazolo-piperidinone inhibitors targeting YAP:TEAD interaction and development of a fluorescence anisotropy assay for high-throughput screening 153
One Health Approach in Drug Discovery for Leishmaniasis by Targeting Calpain cys-protease. 150
MS Proteomics And Biochemical Characterization Of Thymidylate Synthase Dimer Destabilizer E7 To Halt Colorectal Carcinoma 149
Discovery of guanidino-containing benzimidazoles as novel antifolates for Trypanosomiasis 148
integrazione della proteomica mediante spettrometria di massa nel processo di Drug Discovery come strumento innovativo per superare la farmacoresistenza 141
Development of guanidino-containing benzimidazoles as novel folate enzymes inhibitors for the treatment of Human African Trypanosomiasis 138
Promoting A Sustainable Medicinal Chemistry Approach With The Cost Action CA21111 - One Health Drugs Against Parasitic Vector Borne Diseases In Europe And Beyond 133
Leveraging proteomics, bioinformatics, and ecotoxicology models to select new targets overcoming L infantum drug resistance. 132
Targeting of the Cysteines Surface domain of the Transcriptional Enhancer Associate Domain (TEAD) for anticancer drug discovery 125
Structural insight into YAP-TEAD4 protein-protein interactions as target for cancer treatment 120
Proteomic contribution to the omic path for the identification of novel drugs overcoming resistance in Leishmaniasis. 120
Preclinical investigation of H80 compared to miltefosine: imaging and proteomics for sustainable drug development 107
Development of a fluorescent anisotropy displacement assay for the optimization of YAP:TEAD molecular disrupters with anticancer activity 89
IDENTIFICATION OF PYRAZOLO-PIPERIDINONE DERIVATIVES TARGETING YAP-TEAD INTERFACE 3 AS ANTICANCER AGENTS THROUGH INTEGRATED VIRTUAL SCREENING AND MASS SPECTROMETRY PROTEOMICS 74
Totale 10.517
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.611
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.611
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202130 0 0 0 0 0 0 0 0 0 0 0 30
2021/2022369 26 12 2 2 2 47 18 32 50 41 85 52
2022/2023830 87 69 30 61 76 58 80 97 121 31 70 50
2023/20241.247 59 76 84 71 312 85 84 103 36 40 163 134
2024/20253.151 109 43 120 193 536 451 206 235 316 141 391 410
2025/20264.866 458 303 428 592 609 275 642 235 435 486 297 106
Totale 10.517